Xpovio® (selinexor) approved for commercialization in indonesia, further expanding antengene's commercial presence in apac

- xpovio ® is the first and only approved xpo1 inhibitor in indonesia. - from the second half of 2024 to now, xpovio ®  was successively approved in thailand, malaysia and indonesia, significantly expanding antengene's commercial presence in apac.
KPTI Ratings Summary
KPTI Quant Ranking